 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| Pharmacokinetic data | |
| Bioavailability | 80-90 % |
| Metabolism | 22-38 % |
| Elimination half-life | 0.12 – 0.17 h-1 |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C15H11NO3 |
| Molar mass | 253.257 g·mol−1 |
| Melting point | 229–230 °C (444–446 °F) |
| Solubility in water | <15 in H2O mg/mL (20 °C) |
Furegrelate, also known as 5-(3-pyridinylmethyl)benzofurancarboxylic acid, is a chemical compound with thromboxane enzyme inhibiting properties that was originally developed by Pharmacia Corporation as a drug to treat arrhythmias, ischaemic heart disorders, and thrombosis[1] but was discontinued. It is commercially available in the form furegrelate sodium salt.
Furegrelate is able to bind to the enzyme thromboxane A2 synthase. By binding to thromboxane A2 synthase it negates the effects and prevents it from acting like a vasoconstrictor. Because of this Furegrelate is capable of preventing several diseases involving thrombosis, the occurrence of blood clots that block veins or arteries. Furegrelate is orally administrable and rapidly absorbed in the blood. Currently no adverse effects of furegrelate are known due to a lack of research, although thromboxane A2 synthase devisentie could be a potential risk.
- ^ "Furegrelate". Adis Insight. Springer Nature Switzerland AG.